- Home
- ARVN vs TRTX Comparison
ARVN vs TRTX Comparison
Compare ARVN & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- TRTX
- Stock Information
- Founded
- ARVN 2015
- TRTX 2014
- Country
- ARVN United States
- TRTX United States
- Employees
- ARVN N/A
- TRTX N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- TRTX Real Estate Investment Trusts
- Sector
- ARVN Health Care
- TRTX Real Estate
- Exchange
- ARVN Nasdaq
- TRTX Nasdaq
- Market Cap
- ARVN 676.2M
- TRTX 708.3M
- IPO Year
- ARVN 2018
- TRTX 2017
- Fundamental
- Price
- ARVN $10.59
- TRTX $8.94
- Analyst Decision
- ARVN Buy
- TRTX Buy
- Analyst Count
- ARVN 23
- TRTX 3
- Target Price
- ARVN $17.80
- TRTX $10.75
- AVG Volume (30 Days)
- ARVN 2.3M
- TRTX 502.5K
- Earning Date
- ARVN 11-05-2025
- TRTX 10-28-2025
- Dividend Yield
- ARVN N/A
- TRTX 10.73%
- EPS Growth
- ARVN N/A
- TRTX N/A
- EPS
- ARVN N/A
- TRTX 0.65
- Revenue
- ARVN $312,300,000.00
- TRTX $138,590,000.00
- Revenue This Year
- ARVN N/A
- TRTX N/A
- Revenue Next Year
- ARVN N/A
- TRTX $6.62
- P/E Ratio
- ARVN N/A
- TRTX $13.81
- Revenue Growth
- ARVN 93.86
- TRTX 4.13
- 52 Week Low
- ARVN $5.90
- TRTX $6.47
- 52 Week High
- ARVN $27.00
- TRTX $9.85
- Technical
- Relative Strength Index (RSI)
- ARVN 59.44
- TRTX 52.54
- Support Level
- ARVN $9.27
- TRTX $8.82
- Resistance Level
- ARVN $11.51
- TRTX $9.12
- Average True Range (ATR)
- ARVN 0.53
- TRTX 0.21
- MACD
- ARVN 0.02
- TRTX 0.02
- Stochastic Oscillator
- ARVN 59.15
- TRTX 50.00
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.